External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

Solara Active Pharma Sciences / Equity Bottom-Up

Solara Active Pharma Sciences (SOLARA IN)

<p>We expect Gross Margins to be impacted due to an increase in revenue share from non-regulated markets and an increase in raw material prices going onwards. Hence, we recommend a HOLD rating on the stock with a target price of INR 1,670 (PE 20x for FY23EPS).</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

We expect Gross Margins to be impacted due to an increase in revenue share from non-regulated markets and an increase in raw material prices going onwards. Hence, we recommend a HOLD rating on the stock with a target price of INR 1,670 (PE 20x for FY23EPS).Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Solara Active Pharma Sciences: Gross Margins Impacted